The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

GNAQ/11 Woodman article

Forums Ocular Melanoma Community GNAQ/11 Woodman article

  • Post
    edamaser
    Participant

      Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ and GNA11 Dependent Manner

      1. Scott E. Woodman6,*

      + Author Affiliations


      1. 1Melanoma Medical Oncology, MD Anderson Cancer Center

      2. 2Thoracic and Cardiovascular surgery, MD Anderson cancer Center

      3. 3Melanoma Medical Oncology and Systems Biology, M. D. Anderson Cancer Center

      4. 4Melanoma Medical Oncology, M.D. Anderson Cancer Center

      5. 5Head and Neck Surgery, Section of Ophthalmology, MD Anderson Cancer Center

      6. 6Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
      1. *Corresponding Author:
        Scott E. Woodman, Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, South Campus Research Building, SCR 2.3022, 7455 Fannin St., Houston, TX, 77054, United States [email protected]

      Abstract

      Purpose: Activating-Q209L/P mutations in GNAQ or GNA11 (GNAQ/11) are present in ∼80% of uveal melanomas (UM). Mutant GNAQ/11 are not currently therapeutically targetable. Inhibiting key downstream effectors of GNAQ/11 represents a rational therapeutic approach for UMs that harbor these mutations. The MEK/MAPK and PI3K/AKT pathways are activated in UM. In this study, we test the effect of the clinically relevant small molecule inhibitors GSK1120212 (MEK inhibitor) and GSK2126458 (pan class I PI3K inhibitor) on UM cells with different GNAQ/11 mutations. Experimental Design: We use the largest set of genetically annotated uveal melanoma cell lines to-date to perform in vitro cellular signaling, cell cycle regulation, growth and apoptosis analyses. RNA interference and small molecule MEK and/or PI3K inhibitor treatment were employed to determine the dependency of cells with different GNAQ/11 mutation backgrounds on MEK/MAPK and/or PI3K/AKT signaling. Proteomic network analysis was performed to unveil signaling alterations in response to MEK and/or PI3K inhibition. Results: GNAQ/11 mutation status was not a determinant of whether cells would undergo cell cycle arrest or growth inhibition to MEK and/or PI3K inhibition. A reverse correlation was observed between MAPK and AKT phosphorylation after MEK or PI3K inhibition, respectively. Neither MEK nor PI3K inhibition alone was sufficient to induce apoptosis in the majority of cell lines; however, the combination of MEK + PI3K inhibitor treatment caused marked apoptosis in a GNAQ/11 mutant-dependent manner. Conclusions: MEK + PI3K inhibition may be an effective combination therapy in uveal melanoma given the inherent reciprocal activation of these pathways in UM.

      • Received December 14, 2011.
      • Revision received May 30, 2012.
      • Accepted June 1, 2012.
    Viewing 5 reply threads
    • Replies
        RobC
        Participant

          thanks for posting this Esther – Scott mentioned this MEKi+ PI3K combination at the meeting so it's good to see some early positive results

          RobC
          Participant

            thanks for posting this Esther – Scott mentioned this MEKi+ PI3K combination at the meeting so it's good to see some early positive results

            RobC
            Participant

              thanks for posting this Esther – Scott mentioned this MEKi+ PI3K combination at the meeting so it's good to see some early positive results

              paperdetective
              Participant

                Great news, Esther. It looks like science is really going to make a difference now in our OM treatment.

                 

                Peter L in NH

                paperdetective
                Participant

                  Great news, Esther. It looks like science is really going to make a difference now in our OM treatment.

                   

                  Peter L in NH

                  paperdetective
                  Participant

                    Great news, Esther. It looks like science is really going to make a difference now in our OM treatment.

                     

                    Peter L in NH

                Viewing 5 reply threads
                • You must be logged in to reply to this topic.
                About the MRF Patient Forum

                The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

                The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.